Nitric oxide (NO) maintains cardiovascular health by activating soluble guanylate cyclase (sGC) to increase cellular cGMP levels. Cardiovascular disease is characterized by decreased NO-sGC-cGMP signaling. Pharmacological activators and stimulators of sGC are being actively pursued as therapies for acute heart failure and pulmonary hypertension. Here we review molecular mechanisms that modulate sGC activity while emphasizing a novel biochemical pathway in which binding of the matricellular protein thrombospondin-1 (TSP1) to the cell surface receptor CD47 causes inhibition of sGC. We discuss the therapeutic implications of this pathway for blood flow, tissue perfusion, and cell survival under physiologic and disease conditions. © 2014 Rogers, Seeger, Garcin, Roberts and Isenberg.
CITATION STYLE
Rogers, N. M., Seeger, F., Garcin, E. D., Roberts, D. D., & Isenberg, J. S. (2014). Regulation of soluble guanylate cyclase by matricellular thrombospondins: Implications for blood flow. Frontiers in Physiology. Frontiers Media SA. https://doi.org/10.3389/fphys.2014.00134
Mendeley helps you to discover research relevant for your work.